Raludotatug Deruxtecan
Based on 1 Customer Validation
Raludotatug Deruxtecan is an antibody-drug conjugate targeting CDH6, with an EC50 of 64.7 ng/mL in humans, 70.4 ng/mL in cynomolgus monkeys, and 228 ng/mL in mice. Raludotatug Deruxtecan specifically binds to CDH6 on the surface of cancer cells, triggers lysosomal internalization, and releases the DXd payload that inhibits TOP1. Raludotatug Deruxtecan induces DNA damage, Chk1 phosphorylation, caspase-3 cleavage, apoptosis, and bystander cell death. Raludotatug Deruxtecan is applicable to research related to serous ovarian cancer and renal cell carcinoma.
For research use only. We do not sell to patients.
- Purity : 98.68%
- CAS No.: 2610074-57-0
-
Storage:
-80°C, protect from light
Biological Activity
Description
In Vitro
Raludotatug deruxtecan (R-DXd) (0.001-1000 ng/mL; 6 days) exerts CDH6-dependent cell growth-inhibitory activity, potently inhibiting growth of CDH6-positive NIH:OVCAR-3 and PA-1 ovarian cancer cells, while having no effect on CDH6-negative ES-2 ovarian cancer cells[1].
Raludotatug deruxtecan (R-DXd) (0.001-1000 ng/mL; 6 days) exerts CDH6-dependent cell growth-inhibitory activity, as its cytotoxic effect is abrogated in CDH6-knockout NIH:OVCAR-3 cells despite preserved sensitivity to free DXd[1].
Raludotatug deruxtecan (R-DXd) (10 ng/mL; 6, 8, or 10 days) exhibits a bystander antitumor effect, where payload released from CDH6-positive cells diffuses to kill adjacent CDH6-negative cells[1].
Raludotatug deruxtecan (R-DXd) (3 μg/mL; 3 days) induces DNA damage and apoptosis in CDH6-positive PA-1 ovarian cancer cells[1].
Raludotatug deruxtecan (R-DXd) (10 nmol/L; 0, 0.5, 1, 3, 6, 12, 24, or 48 hours at 37°C) exhibits high internalization efficiency in CDH6-positive NIH:OVCAR-3 ovarian cancer cells, with nearly complete internalization within 24 hours[1].
Raludotatug deruxtecan (R-DXd) (10 nmol/L; 0, 0.5, 1, 3, 6, 12, 24, or 48 hours at 37°C) reduces cell-surface CDH6 expression in CDH6-positive NIH:OVCAR-3 ovarian cancer cells, but CDH6 expression recovers rapidly if unbound R-DXd is removed from the medium[1].
Raludotatug deruxtecan (R-DXd) (10 μg/mL; up to 24 hours at 37°C) binds to CDH6 at cell-cell boundaries, is internalized, and traffics to lysosomes in CDH6-expressing CHO-K1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:CDH6-positive human ovarian cancer cell lines (NIH:OVCAR-3, PA-1) and CDH6-negative human ovarian cancer cell line (ES-2)
-
Concentration:0.001-1000 ng/mL
-
Incubation Time:6 days
-
Result:Potently inhibited growth of CDH6-positive NIH:OVCAR-3 and PA-1 cells. Showed no growth-inhibitory activity against CDH6-negative ES-2 cells.
-
Cell Line:Parental CDH6-positive NIH:OVCAR-3 cells and CDH6-knockout NIH:OVCAR-3 (KO-OVCAR-3) cells
-
Concentration:0.001-1000 ng/mL
-
Incubation Time:6 days
-
Result:Potently inhibited growth of parental NIH:OVCAR-3 cells. Showed severely weakened growth-inhibitory activity against KO-OVCAR-3 cells (which retain sensitivity to free DXd).
-
Cell Line:CDH6-positive PA-1 human ovarian cancer cells
-
Concentration:3 μg/mL
-
Incubation Time:3 days
-
Result:Induced phosphorylation of Chk1 (a DNA damage marker). Induced cleavage of caspase-3 (an apoptosis marker).
Parmacokinetics
In Vivo
Raludotatug Deruxtecan (10 mg/kg; i.v.; days 0 and 21) induces significant tumor regression in CDH6-positive ovarian and renal cell carcinoma patient-derived xenograft models, but not in CDH6-negative models[1].
Raludotatug Deruxtecan (3 mg/kg; i.v.; single dose on day 0 for PA-1 models; 10 mg/kg; i.v.; single dose on day 0 for JHOC-5 models) exhibits equivalent antitumor efficacy in parental and sCDH6-overexpressing ovarian cancer xenografts, indicating sCDH6 does not inhibit its activity[1].
Raludotatug Deruxtecan (10-80 mg/kg; i.v.; once every 3 weeks for 6 weeks for 10, 30 mg/kg; single dose for 80 mg/kg) has a highest non-severely toxic dose of 30 mg/kg in cynomolgus monkeys, with mild-to-moderate, mostly reversible toxicity observed at this dose[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CAnN.Cg-Foxn1^nu/CrlCrlj (female, 4 to 5 weeks old)[1]
-
Dosage:0.25-10 mg/kg (single dose)
-
Administration:i.v.; single dose on day 0
-
Result:Induced tumor regression in NIH:OVCAR-3 xenografts with final tumor volumes near 0 mm3 at 3 mg/kg. Induced tumor regression in 786-O xenografts, but showed no significant effect on CDH6-negative ES-2 xenografts at 10 mg/kg.
-
Animal Model:CAnN.Cg-Foxn1^nu/CrlCrlj (female, 4 to 5 weeks old)[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; single dose
-
Result:Induced tumor regression in carboplatin- and paclitaxel-refractory NIH:OVCAR-3 xenografts with final tumor volumes near 0 mm3. Caused no serious body weight loss.
Chemical Information
-
CAS No. 2610074-57-0
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Raludotatug Deruxtecan]
-
Synonyms
R-DXd; DS-6000
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)